Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
September 20, 2024 07:30 ET
|
Traws Pharma, Inc.
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of...
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
September 17, 2024 16:05 ET
|
Traws Pharma, Inc.
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading on...
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
August 15, 2024 07:00 ET
|
Traws Pharma, Inc.
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical...
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
August 14, 2024 16:30 ET
|
Traws Pharma, Inc.
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral...
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
May 23, 2024 08:00 ET
|
Traws Pharma, Inc.
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024 09:29 ET
|
Traws Pharma, Inc.
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
May 07, 2024 08:00 ET
|
Traws Pharma, Inc.
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
Traws Pharma Announces New Employee Inducement Grants
April 02, 2024 07:15 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in...
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
April 02, 2024 07:00 ET
|
Onconova Therapeutics, Inc.
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey PinesFunding expected to advance development of three potential...
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
March 08, 2024 08:00 ET
|
Onconova Therapeutics, Inc.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024